Titan shares rise 5% on positive revenue growth in Q3

Titan’s profit margin was primarily affected due to rise in expenses and 6 times higher gold ingot sales in the third quarter of financial year 2023. The company’s total expenses came at Rs 9,699 crore increasing 13.7 percent from Rs 8523 in the corresponding period a year ago.

The company also sold gold ingot worth Rs 315 crore in the quarter as compared to the sale of the same worth Rs 54 crore in the corresponding period a year ago, as notified by Titan in a business update.

Gold ingots are basically gold bars. Jewellery companies use gold ingots to preserve gold to make gold jewellery. They are technically raw material for the company hence there is no profit margin on its sale.

Titan’s jewellery business recorded a growth of revenue growth of 14.1 percent in the quarter at Rs 9,833 crore. Earnings Before Interest and Taxes (EBIT) declined 1.96 percent and came at Rs 1,236 crore.

The company's India business grew by 9 percent in the same period, backed by healthy consumer demand during the festive season. The customer walk-ins were robust and consumer preference for differentiated designs were prominent across categories, Titan said in its financial results for the quarter.

The watches and wearables business witnessed a revenue growth of 42.5 percent. Buoyed by new product launches, the business reported an EBIT of Rs 89 crores clocking an EBIT margin of 11 percent.

The eyecare/eyewear business grew 12 percent. Titan reported an EBIT of Rs 32 crore, clocking an EBIT margin of 18.4 percent. The company also opened its first international store in Dubai in December 2022.

Caratlane continued to contribute 75 percent of the total business to the company. The total Income for Caratlane grew by 51 percent as compared to the corresponding fiscal, to Rs 677 crore, driven by gifting campaigns around the festive season, Titan said in the regulatory filing.

Shares closed at Rs 2,304, or down 1.8 percent, from the previous close on the Bombay Stock Exchange (BSE).